Human Longevity vs CoverMyMeds

Side-by-side comparison of AI visibility scores, market position, and capabilities

Human Longevity logo

Human Longevity

ChallengerHealthcare

Precision Health & Genomics

Human Longevity Inc. offers comprehensive executive health programs combining whole-genome sequencing, full-body MRI, 120+ biomarkers, and AI analysis; launched a longevity app in 2026 and added Nobel laureate advisors.

About

Human Longevity, Inc. (HLI) is a biotechnology and precision health company founded in 2013, applying genomics, multimodal diagnostics, and artificial intelligence to extend human healthspan. The company offers what it describes as the most comprehensive executive health assessment available: a single integrated program combining whole-genome sequencing, full-body MRI, more than 120 biomarkers, microbiome analysis, and AI-driven interpretation — all delivered in one visit. Members receive personalized early-detection screening, treatment plans, and continuous health monitoring through HLI''s Executive Health Program and its 100+ Longevity Programs.

Full profile
CoverMyMeds logo

CoverMyMeds

LeaderHealthcare Revenue Cycle & Health IT

Prior Authorization & Medication Access

Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies;

AI VisibilityBeta
Overall Score
A90
Category Rank
#1 of 1
AI Consensus
84%
Trend
up
Per Platform
ChatGPT
98
Perplexity
97
Gemini
92

About

CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.

Full profile

Key Details

Category
Precision Health & Genomics
Prior Authorization & Medication Access
Tier
Challenger
Leader
Entity Type
brand
product

Capabilities & Ecosystem

Capabilities

Only CoverMyMeds
Prior Authorization & Medication Access
CoverMyMeds is classified as product (part of McKesson).

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.